

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**RemeGen Co., Ltd.\***

**榮昌生物製藥（煙台）股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 9995)**

## **DISCLOSEABLE TRANSACTION PURCHASE OF WEALTH MANAGEMENT PRODUCT**

### **PURCHASE OF WEALTH MANAGEMENT PRODUCT**

At the 21st meeting held by the second session of the Board on March 27, 2025, a resolution regarding cash management using self-owned funds of the Company was considered and approved, pursuant to which the Company may purchase principal guaranteed bank wealth management products using part of idle self-owned funds of not more than RMB500.0 million.

The Board announced that, on August 29, 2025, the Company entered into the SPDB Wealth Management Product Agreement with SPDB Yantai Branch, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB300.0 million from SPDB Yantai Branch using idle self-owned funds.

### **LISTING RULES IMPLICATIONS**

As the Company entered into two other wealth management product agreements with SPDB in July 2025 and still holds the wealth management products under these agreements, the transactions contemplated under these wealth management product agreements and the SPDB Wealth Management Product Agreement are conducted with the same bank and are of similar nature within a 12-month period. For the purpose of calculating the relevant percentage ratios under Rule 14.22 of the Listing Rules, these transactions shall be aggregated in each case as if they were one transaction with the said bank.

As one of the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules) in respect of the SPDB Wealth Management Product Agreement (calculated on an aggregation basis with the aforesaid two other wealth management product agreements) exceeds 5% but all of the applicable percentage ratios are less than 25%, the purchase of wealth management product under the SPDB Wealth Management Product Agreement therefore constitutes a discloseable transaction of the Company under Chapter 14 of the Listing Rules and is subject to the reporting and announcement requirements under the Listing Rules.

## BACKGROUND

The Board announced that, on August 29, 2025, the Company entered into the SPDB Wealth Management Product Agreement with SPDB Yantai Branch, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB300.0 million from SPDB Yantai Branch using idle self-owned funds.

## SPDB WEALTH MANAGEMENT PRODUCT AGREEMENT

The principal terms of the SPDB Wealth Management Product Agreement are set out as follows:

Name of product	:	Li Duoduo Corporate Stable Profits 25JG3363 Period (Monthly Compound Interest Exclusive Payment B) RMB Corporate Structured Deposit (利多多公司穩利25JG3363期(月月滾利特供款B)人民幣對公結構性存款)
Type of product	:	Principal-guaranteed with floating income
Linked target	:	EUR-USD exchange rate
Principal amount	:	RMB300.0 million
Validity period of product	:	29 days
Effective date of product	:	September 1, 2025
Expiry date of product	:	September 30, 2025
Expected annualized yield rate	:	0.7% or 2.05% or 2.25%
Right of early termination	:	SPDB Yantai Branch has the right to early terminate the agreement.
Investment scope	:	The proceeds from the sales of this structured deposit product will be nominal principal, the capital costs of which will be used to enter into transactions with counterparty to make investment in financial derivatives linked to the counterparty's investment income and the EUR-USD spot rate

The terms of the SPDB Wealth Management Product Agreement were determined upon arm's length negotiations between the parties.

## **PRIOR PURCHASES**

In July 2025, the Company entered into two wealth management product agreements with SPDB Yantai Branch, pursuant to which the Company agreed to purchase (i) a principal-guaranteed with floating income wealth management product in the amount of RMB100.0 million with the proceeds from the issuance of A shares of the Company from SPDB Yantai Sub-branch, with a term of 96 days and an expected annualised yield rate of 0.7% or 2.04% or 2.24%; and (ii) a principal-guaranteed with floating income wealth management product in the amount of RMB150.0 million with idle internal funds from SPDB Yantai Sub-branch, with a term of 28 days and an expected annualised yield rate of 0.7% or 2.00% or 2.20%, respectively.

## **INFORMATION ON THE PARTIES**

The Company is a commercial-ready biopharmaceutical company committed to the discovery, development and commercialization of innovative and differentiated biologics for the treatment of autoimmune, oncology and ophthalmic diseases with unmet medical needs in China and globally.

SPDB is a bank incorporated in the PRC, the shares of which are listed on the Shanghai Stock Exchange (stock code: 600000). The principal businesses of SPDB are the provision of corporate and personal banking services, conducting treasury business, and the provision of asset management and other financial services. SPDB Yantai Branch is a branch of SPDB.

To the best knowledge, information and belief of the Directors having made all reasonable enquiries, SPDB Yantai Branch, SPDB and their ultimate substantial beneficial owners as publicly disclosed by SPDB are third parties independent from the Company and its connected persons.

## **REASONS FOR AND BENEFITS OF ENTERING INTO THE SPDB WEALTH MANAGEMENT PRODUCT AGREEMENT**

The reasonable and efficient use of idle self-owned funds will enhance the overall capital gain of the Company, which is consistent with the core objectives of the Company to ensure capital safety and liquidity. The impact of risk factors on the expected return of the SPDB Wealth Management Product Agreement is low, but the Company could get a higher rate of return as compared with fixed-term deposit in commercial banks in the PRC.

The Directors consider that the terms of the SPDB Wealth Management Product Agreement and the transaction contemplated thereunder are fair and reasonable, on normal commercial terms or better in the ordinary course of business of the Group, and are in the interests of the Company and its Shareholders as a whole.

## LISTING RULES IMPLICATIONS

As the Company entered into two other wealth management product agreements with SPDB in July 2025 and still holds the wealth management products under these agreements, the transactions contemplated under these wealth management product agreements and the SPDB Wealth Management Product Agreement are conducted with the same bank and are of similar nature within a 12-month period. For the purpose of calculating the relevant percentage ratios under Rule 14.22 of the Listing Rules, these transactions shall be aggregated in each case as if they were one transaction with the said bank.

As one of the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules) in respect of the SPDB Wealth Management Product Agreement (calculated on an aggregation basis with the aforesaid two other wealth management product agreements) exceeds 5% but all of the applicable percentage ratios are less than 25%, the purchase of wealth management product under the SPDB Wealth Management Product Agreement therefore constitutes a discloseable transaction of the Company under Chapter 14 of the Listing Rules and is subject to the reporting and announcement requirements under the Listing Rules.

## DEFINITIONS

Unless the context otherwise requires, the following terms used herein have the following meanings:

“Board”	the board of Directors
“Company”	RemeGen Co., Ltd.* (榮昌生物製藥(煙台)股份有限公司), a company incorporated in the PRC with limited liability, the H shares and A shares of which are listed on the Main Board of the Stock Exchange (stock code: 9995) and the Science and Technology Innovation Board of the Shanghai Stock Exchange (stock code: 688331), respectively
“connected person”	has the meaning ascribed to it under the Listing Rules
“Director(s)”	the director(s) of the Company
“EUR”	the lawful currency of the European Union
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“PRC” or “China”	the People’s Republic of China excluding, for the purpose of this announcement, Hong Kong, the Macau Special Administrative Region of the People’s Republic of China and Taiwan
“RMB”	Renminbi, the lawful currency of the PRC

“Shareholder(s)”	holder(s) of the shares of the Company
“SPDB”	Shanghai Pudong Development Bank Co., Ltd., a bank incorporated in the PRC
“SPDB Wealth Management Product Agreement”	the wealth management product agreement entered into between the Company and SPDB Yantai Branch dated August 29, 2025 in relation to the purchase of wealth management product in the amount of RMB300.0 million
“SPDB Yantai Branch”	Yantai Branch of Shanghai Pudong Development Bank Co., Ltd.
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“USD”	United States dollar, the lawful currency of the United States of America
“%”	percent

By order of the Board  
**RemeGen Co., Ltd.\***  
**Mr. Wang Weidong**  
*Chairman and executive Director*

Yantai, PRC  
August 29, 2025

*As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Lin Jian and Mr. Wen Qingkai as the executive Directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive Directors, and Mr. Hao Xianjing, Mr. Chen Yunjin and Mr. Huang Guobin as the independent non-executive Directors.*

\* *For identification purpose only*